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Abstract
© 2017 The Author(s). Endothelial cells (EC) play a key role in atherosclerosis. Although EC are
in constant contact with low density lipoproteins (LDL), how EC process LDL and whether this
influences atherogenesis, is unclear. Here we show that EC take up and metabolize LDL, and
when overburdened with intracellular cholesterol, generate cholesterol crystals (CC). The CC are
deposited on the basolateral side, and compromise endothelial function. When hyperlipidemic
mice are given a high fat diet, CC appear in aortic sinus within 1 week. Treatment with cAMP-
enhancing agents, forskolin/rolipram (F/R), mitigates effects of CC on endothelial function by not
only improving barrier function, but also inhibiting CC formation both in vitro and in vivo. A proof
of  principle  study  using  F/R  incorporated  into  liposomes,  designed  to  target  inflamed
endothelium, shows reduced atherosclerosis and CC formation in ApoE -/- mice. Our findings
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